Scienza e Tecnologia
Telix to Present at Jefferies London Healthcare Conference 2022
A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff255/tlx/1728648
The webcast will be accessible on demand on the Telix website following the event.
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United States , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix's lead product, gallium-68 ( Ga) gozetotide (also known as Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA), and by the Australian Therapeutic Goods Administration (TGA), and by Health Canada.
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com
[1] ASX disclosure 20 December 2021 .
[2] ASX disclosure 2 November 2021 .
[3] ASX disclosure 14 October 2022 .
Legal Notices
Logo - https://mma.prnewswire.com/media/1920208/TeliMain_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/telix-to-present-at-jefferies-london-healthcare-conference-2022-301675554.html